DDInter1215 DDInter1676
Mifepristone is a progestational and glucocorticoid hormone antagonist. Its inhibition of progesterone induces bleeding during the luteal phase and in early pregnancy by releasing endogenous prostaglandins from the endometrium or decidua. As a glucocorticoid receptor antagonist, the drug has been used to treat hypercortisolism in patients with nonpituitary cushing syndrome. The two marketed forms of mifepristone are Mifeprex® (mifepristone 200mg) and Korlym™ (mifepristone 300mg). Currently under investigation for use in psychotic depression (phase 3 trials).
Siponimod, also known as _Mayzent_, by Novartis, is a new drug formulated for the management of Multiple Sclerosis (MS). It was approved by the FDA on March 26, 2019 and by Health Canada on February 20, 2020. This drug is considered a _sphingosine-1-phosphate (S1P) receptor modulator_ and is thought to play a role in suppressing the central nervous system inflammation that is associated with MS [FDA label]. Multiple Sclerosis (MS) is an autoimmune disease of the central nervous system that is chronic and inflammatory, disrupting communication between the brain and other parts of the body. Most patients diagnosed with this illness experience their initial disease symptoms between the age of 20 to 40, often the most productive years of life. Symptoms may include but are not limited to fatigue, gait changes, bowel or bladder dysfunction, abnormal muscle twitching, vision disturbance, and depressing or mood swings. MS is one of the most common causes of neurological disability in young adults and is found to occur more frequently in women than in men.[A176474,L5792]
Mifepristone {u} (Compound) binds {v} (Gene) CYP3A5
Mifepristone {u} (Compound) upregulates {v} (Gene) CDK6
Mifepristone {u} (Compound) is included by {v} (Pharmacologic Class) Progestational Hormone Receptor Antagonists
Mifepristone {u} (Compound) downregulates {v} (Gene) ATP6V1D
Mifepristone {u} (Compound) causes {v} (Side Effect) Toxic shock syndrome
Mifepristone {u} may cause a minor interaction that can limit clinical effects when taken with {v} Bexarotene
Mifepristone {u} may cause a minor interaction that can limit clinical effects when taken with {v} Metronidazole
Mifepristone {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Naldemedine
Mifepristone {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Chloramphenicol
Mifepristone {u} may lead to a major life threatening interaction when taken with {v} Daunorubicin
Mifepristone (Compound) binds CYP3A5 (Gene)
Mifepristone (Compound) upregulates CDK6 (Gene)
Mifepristone (Compound) is included by Progestational Hormone Receptor Antagonists (Pharmacologic Class)
Mifepristone (Compound) downregulates ATP6V1D (Gene)
Mifepristone (Compound) causes Toxic shock syndrome (Side Effect)
Mifepristone may cause a minor interaction that can limit clinical effects when taken with Bexarotene
Mifepristone may cause a minor interaction that can limit clinical effects when taken with Metronidazole
Mifepristone may cause a moderate interaction that could exacerbate diseases when taken with Naldemedine
Mifepristone may cause a moderate interaction that could exacerbate diseases when taken with Chloramphenicol
Mifepristone may lead to a major life threatening interaction when taken with Daunorubicin